Encouraging Results in Advanced Gastroenteropancreatic Neuroendocrine Tumors Phase III Trials
source: shutterstock.com

Encouraging Results in Advanced Gastroenteropancreatic Neuroendocrine Tumors Phase III Trials

The primary outcome from the Phase III NETTER-2 clinical trial as reported recently in Globe Newswire, was heralded as extending progression free survival from 8.5 months to 22.8. The participants…

Continue Reading Encouraging Results in Advanced Gastroenteropancreatic Neuroendocrine Tumors Phase III Trials
November 10 is World NET Cancer Day: Spreading Rare Disease Awareness
source: shutterstock.com

November 10 is World NET Cancer Day: Spreading Rare Disease Awareness

November 10 is recognized as World Neuroendocrine Tumor (NET) Cancer Day, a time to spread awareness about neuroendocrine tumors, a group of rare cancers, among the medical field and in…

Continue Reading November 10 is World NET Cancer Day: Spreading Rare Disease Awareness
Surufatinib Approved in China For the Treatment of Pancreatic Neuroendocrine Tumors
https://unsplash.com/photos/_jbClosDsD4

Surufatinib Approved in China For the Treatment of Pancreatic Neuroendocrine Tumors

The National Medical Products Administration (NMPA) of China has recently approved surufatinib for drug registration for the treatment of advanced pancreatic neuroendocrine tumors (pNETs). HUTCHMED Limited recently announced the news,…

Continue Reading Surufatinib Approved in China For the Treatment of Pancreatic Neuroendocrine Tumors
Four New Rare Disease Studies Receive $19 Million in Funding
source: pixabay.com

Four New Rare Disease Studies Receive $19 Million in Funding

The Patient-Centered Outcomes Research Institute (PCORI) has announced that it will be contributing funding for four new studies focused on four different rare diseases. The funding will top out at…

Continue Reading Four New Rare Disease Studies Receive $19 Million in Funding
Neuroendocrine Tumors Trial Results Demonstrate Preserved Quality of Life With Doubled Treatment Dose
source: pixabay.com

Neuroendocrine Tumors Trial Results Demonstrate Preserved Quality of Life With Doubled Treatment Dose

According to a story from businesswire.com, the biopharmaceutical company Ipsen recently presented a total of 9 study abstracts at the recent 18th annual conference of the European Neuroendocrine Tumor Society…

Continue Reading Neuroendocrine Tumors Trial Results Demonstrate Preserved Quality of Life With Doubled Treatment Dose
FDA Approves PRRT to Treat Neuroendocrine Tumors
source: pixabay.com

FDA Approves PRRT to Treat Neuroendocrine Tumors

  Patients with inoperable or metastasized neuroendocrine tumors (NETs) may now benefit from recently FDA approved peptide receptor radionuclide therapy (PRRT) according to a recent article in MedPage Today. The…

Continue Reading FDA Approves PRRT to Treat Neuroendocrine Tumors
FDA Grants Orphan Drug Designation for Treatment of Pancreatic Neuroendocrine Tumors
source: pixabay.com

FDA Grants Orphan Drug Designation for Treatment of Pancreatic Neuroendocrine Tumors

  Surufatinib was recently granted Orphan Drug designation by the FDA. This drug was made for the treatment of pancreatic neuroendocrine tumors (PanNETs). It was created by Hutchison China MediTech…

Continue Reading FDA Grants Orphan Drug Designation for Treatment of Pancreatic Neuroendocrine Tumors
Phase 1 Trial of Experimental Treatment for Neuroendocrine Tumors Begins
bdyczewski / Pixabay

Phase 1 Trial of Experimental Treatment for Neuroendocrine Tumors Begins

According to a story from Central Charts, the drug developer Crinetics Pharmaceuticals, Inc. recently issued an announcement revealing that the company has begun the initialization of a Phase 1 clinical…

Continue Reading Phase 1 Trial of Experimental Treatment for Neuroendocrine Tumors Begins

New Treatment for GEP-NETs Approved in Canada

According to a story from pm360online.com, the Novartis company Advanced Accelerator Applications S.A. recently announced that Health Canada has issued approval for Lutathera™ as a treatment for gasteroenteropancreatic neuroendocrine tumors…

Continue Reading New Treatment for GEP-NETs Approved in Canada
FDA Orphan Drug Designation for a New Neuroendocrine Tumor Treatment!
source: pixabay.com

FDA Orphan Drug Designation for a New Neuroendocrine Tumor Treatment!

Neuroendocrine tumors are growths which form from neuroendocrine cells in various places throughout the body. They can occur in the gastrointestinal track, the pancreas, the lungs, the thymus, and other…

Continue Reading FDA Orphan Drug Designation for a New Neuroendocrine Tumor Treatment!
What Killed Aretha Franklin? An In-Depth Look at Pancreatic Neuroendocrine Tumors
IADE-Michoko / Pixabay

What Killed Aretha Franklin? An In-Depth Look at Pancreatic Neuroendocrine Tumors

On August 16th, 2018, Aretha Franklin, the "Queen of Soul," passed away at age 76. Aretha will be immortalized for generations because of the success of her classic soul ballads…

Continue Reading What Killed Aretha Franklin? An In-Depth Look at Pancreatic Neuroendocrine Tumors
A New App has Been Developed to Support the Neuroendocrine Tumour Community
JESHOOTScom / Pixabay

A New App has Been Developed to Support the Neuroendocrine Tumour Community

Novartis has teamed up with Numinous Games to develop Galaxies of Hope, an app that is designed to support the neuroendocrine tumour (NET) community. You can read the original source…

Continue Reading A New App has Been Developed to Support the Neuroendocrine Tumour Community